CareTalk Podcast Episode #20 - Gottlieb's Out. What's Next For FDA?

In this month's episode of #CareTalk, David Williams (Health Business Group) and John Driscoll (CareCentrix) discuss Scott Gottlieb's departure from the FDA, home healthcare spending, Lyft's interest in social determinants of health and much more.
Overview:
(0:28) Scott Gottlieb is out at FDA. Are you sad to see him go?
(2:00) Home health spending is projected to grow faster than any other category of healthcare over the coming years. Is that good or bad?
(4:00) Insulin prices are spiking and both Democrats and Republicans are up in arms. What's happening?
(5:53) Lyft is talking about the social determinants of health. What?!
(8:47) What do you think about FDA approving ketamine nasal spray as a treatment for depression?
(9:10) What did we learn about healthcare from Michael Cohen's Congressional testimony?
(9:33) Medicare has a new app. Have you tried it?
(9:59) Did you hear about the $48,500 bill for a cat bite?
Subscribe to the #CareTalk Podcast
iTunes: apple.co/2DIDTcr
Google Play: bit.ly/2RobqMB

[@CareTalkPodcast]

Hey listeners! What did you think Scott Gottlieb's departure from the FDA? Sound off in the comments!

[@TiborMeszarosTM]

His sudden departure will likely leave many agency efforts to lower costs up in the air.

[@shunnyday]

It's a shame to see Gottlieb go. Let's hope his replacement is half as effective as he was...

[@CareTalkPodcast]

Only time will tell.